MedDataX Logo

Different Lipid Soluble Opioids for Gynecologic Laparoscopic Surgery Postoperative Patient-controlled Analgesia

NCT ID: NCT01917045

Last Updated: 2013-08-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators noticed that Body Fat Ratio might have great influence on the efficacy of different lipid soluble anesthetics. The objective of this clinical trial was to compare the effect of that Body Fat Ratio on the efficacy of different lipid soluble anesthetics.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this clinical trial was to compare the effect of that Body Fat Ratio on the efficacy of different lipid soluble anesthetics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Operative Pain Management

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

sufentanil morphine postoperative pain control body fat percentage gynecology laparoscopic surgery lipid solubility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

low body fat percentage

body fat percentage less than 30%

Group Type EXPERIMENTAL

Sufentanil (R30730, brand name Sufenta)

Intervention Type DRUG

sufentanil 1ug/ml

Sufentanil (R30730, brand name Sufenta) + Morphine

Intervention Type DRUG

sufentanil 0.5ug/ml+morphine 0.25mg/ml

Morphine

Intervention Type DRUG

morphine 0. 5mg/ml

heigh body fat percentage

body fat percentage more than 30%

Group Type EXPERIMENTAL

Sufentanil (R30730, brand name Sufenta)

Intervention Type DRUG

sufentanil 1ug/ml

Sufentanil (R30730, brand name Sufenta) + Morphine

Intervention Type DRUG

sufentanil 0.5ug/ml+morphine 0.25mg/ml

Morphine

Intervention Type DRUG

morphine 0. 5mg/ml

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sufentanil (R30730, brand name Sufenta)

sufentanil 1ug/ml

Intervention Type DRUG

Sufentanil (R30730, brand name Sufenta) + Morphine

sufentanil 0.5ug/ml+morphine 0.25mg/ml

Intervention Type DRUG

Morphine

morphine 0. 5mg/ml

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* American Society of Anesthesiologists grade I-II
* adults aged over 20 and below 50 years old,
* non-smoker,
* with normal hepatic and renal function.

Exclusion Criteria

* smoker ,
* any kind of mental disorder or
* history use of analgesics for more than 10 consecutive days,
* asthma; and
* those with digestion tract disorder who would get nausea or vomiting much more easily than normal people.
Minimum Eligible Age

20 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking University First Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

ZhouYan

M.D

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

zhou yan, MD

Role: PRINCIPAL_INVESTIGATOR

PKU 1st hospital

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LSOPCA-021

Identifier Type: -

Identifier Source: org_study_id